Comparative Evaluation of Razumab and Accentrix in Diabetic Macular Edema: Effects on Visual Acuity and Central Macular Thickness
Keywords:
Razumab, Accentrix, Diabetic Macular Edema (DME), Best Corrected Visual Acuity (BCVA), Central Macular Thickness (CMT), Optical Coherence Tomography (OCT), Intravitreal injection, Intra Ocular Pressure (IOP), Vascular Endothelial Growth Factor (VEGF)Abstract
Background: Diabetic retinopathy is a microvascular disorder occurring as a long-term effect of diabetes mellitus. It may lead to vision-threatening damage to the retina that will eventually lead to blindness. It is the most common cause of severe vision loss in adults of working age groups in India and the Western world. Early detection and timely intervention are crucial in preventing blindness caused by diabetic retinopathy. Currently, anti-VEGF agents are the first-line treatment for central macular edema. Ranibizumab has beneficial effects in patients with baseline good visual acuity. This study aimed to find out the differences between the effects of Biosimilar and cost-effective Razumab and the Innovator brand Accentrix in terms of improving Visual Acuity and reducing Central Macular Thickness.
Materials and Methods: This randomised comparative study was done at Krishna Netralaya from March 2024 to December 2024. A total of 38 eyes were taken having Diabetes and were diagnosed with Diabetic Macular Edema. They were randomly given anti-VEGF injections, Razumab and Accentrix. They were divided into Group R (Razumab)= 14 and Group A (Accentrix)= 24.
Result: Improvement was comparable between two groups, Group A and group R in terms of Visual Acuity (p<0.05) whereas CMT showed statistically significant differences with Accentrix injection (p<0.05), but showed
no statistically significant differences with Razumab injection (p>0.05) with Wilcoxon W test.
Conclusion: Anti VEGF injection is a safe and effective treatment in case of Diabetic Macular Edema irrespective of age at the time of treatment. While both agents are effective in improving visual outcomes, Accentrix offer superior anatomical benefits. Further studies with larger sample sizes and longer follow-up are warranted to confirm these results and guide clinical decision-making
Downloads
Metrics
References
Singh R, Tabano D, Kuo B, LaPrise A, Leng T, Kim E, et al. How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular edema. BMC Ophthalmology volume 24, Article number: 552 (2024)
Yan A, Jones C, Demirel S, Chhablani J. Diabetic macular edema: Upcoming therapies. Volume 263, pages 249-258, (2025)
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomised trials. Ophthalmology. 2012;119(4):789–801.
Sharma A, Holz FG, Kumar N, Sarraf D, Ayachit S, Mishra C et al. Biosimilar ranibizumab (Razumab) in diabetic macular edema: 1-year real-world outcomes. Clin Ophthalmol. 2020;14:3251–3257
Verma A, Kumar S, Agarwal N et al. Safety and efficacy of biosimilar ranibizumab in DME: a prospective observational study. Indian J Ophthalmol. 2020;68(8):1612–1616.
Rajendran A, Narayanasamy A, Balakrishnan D et al. Real-world safety and efficacy of Razumab in retinal disorders: the RE-ENACT 2 study. Indian J Ophthalmol. 2021;69(1):93–99.
Blackstone EA, Fuhr JP Jr. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
D Chakraborty , Sengupta S, Mondal S, Boral S, Das A, Sinha TK et al. Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study. 2022 Apr;11(2):629-638.
Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomised trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.
Li S, Pan J, Xu Y, Dai Z, Fang Q. Exploring the factors influencing the timely intravitreal anti-VEGF treatment in patients with diabetic macular edema: a qualitative interview study using the COM-B model. 2025 Feb 24;25(1):302.
Eisma JH, Dulle JE, Fort PE. Current knowledge on diabetic retinopathy from human donor tissues. World J Diabetes. 2015 Mar 15;6(2):312-20.
Cheema AA, Cheema HR. Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies. Cureus. 2024 Jan 21;16(1):52676
Baek J, He Y, Emamverdi M, Mahmoudi A, Nittala MG, Corradetti G et al. Prediction of Long-Term Treatment Outcomes for Diabetic Macular Edema Using a Generative Adversarial Network.Translational Vision Science & Technology July 2024, Vol.13, 4
Jampol LM, Glassman AR, Bressler NM. Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol. 2016 Dec 1;134(12):10.1001
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
